Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

导出 OA

翻译打印收藏纠错

作者： Klemens,Hoegenauer ^[1] ; Nicolas,Soldermann ^[1] ; Frédéric,Stauffer ^[1] ; Pascal,Furet ^[1] ; Nadege,Graveleau ^[1] ; Alexander B,Smith ^[1] ; Christina,Hebach ^[1] ; Gregory J,Hollingworth ^[1] ; Ian,Lewis ^[1] ; Sascha,Gutmann ^[1] ; Gabriele,Rummel ^[1] ; Mark,Knapp ^[2] ; Romain M,Wolf ^[1] ; Joachim,Blanz ^[1] ; Roland,Feifel ^[1] ; Christoph,Burkhart ^[1] ; Frédéric,Zécri ^[1]

作者单位： Global Discovery Chemistry, Center for Proteomic Chemistry, Metabolism and Pharmacokinetics, Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research , Novartis Campus, CH-4002 Basel, Switzerland. ^[1] Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 5300 Chiron Way, Emeryville, California 94608, United States. ^[2]

关键词 B cell inhibition PI3Kδ inhibitor PK/PD studies Phosphoinositide-3-kinase delta inhibitor lead optimization structure?activity relationship

DOI 10.1021/acsmedchemlett.6b00119

PMID 27563400

发布时间 2024-07-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交